Founded in 2009 by Dr. Philippe Benctueux, Robocath develops and markets robots and intelligent solutions for treating cardiovascular disease, is a pioneering company in the digitalisation of the healthcare sector. The company uses AI to advance interventional medicine.
Its flagship product: the R-One+ platform
Robotcath has developed a robotics platform, R-One+. This product is designed to enhance the precision and comfort of physicians during interventional procedures.
Initially designed for cardiovascular disease, the R-One robot has been tackling the treatment of strokes since 2023. The aim is to treat strokes more quickly and save more lives.
This robot is a real boom in the medical industry, making it possible to anticipate and treat cardiovascular diseases and strokes more effectively.
Strong regional support
Robocath has benefited from substantial support from regional partners such as ADNormandie and the Normandy Region, which have played a crucial role in the development and international expansion of its innovative products.
Exporting to international markets
Over the years, the company has successfully developed and exported its products to various countries in Europe and Africa.
Recently, Robocath decided to conquer Asia, by offering one of its products in China. A joint venture had already been set up with the Chinese group Microport, enabling Robocath to market its R-One platform.
The company is now focusing on developing solutions capable of performing procedures remotely over great distances. This initiative aims to improve access to care for patients with vascular diseases in underserved regions lacking specialized medical facilities.
R-One is the first vascular robotics platform to obtain certification in China, and Robocath’s ultimate goal is to become the world leader in vascular robotics.
